Xeno-Free Strategies for Safe Human Mesenchymal Stem/Stromal Cell Expansion: Supplements and Coatings

Table 1

Successful clinical trials involving hMSC expanded in vitro with FBS-containing medium.

Type of disease	Treatment	Reference
Luminal Crohn’s disease	Allogenic hMSCs	Forbes 2014 [101] ()
Ischemic stroke	Autologous MSCs	Lee 2010 [102] ()
Stroke injury	Autologous MSCs	Bang 2005 [103]
Amyotrophic lateral sclerosis	Intraspinal cord implantation	Mazzini 2008 [104]
Grade IV acute graft-versus-host disease	Haploidentical MSC	Le Blanc 2004 [105]
Brest cancer	Autologous MSCs	Koc 2000 [106]
Acute myocardial infarction	Autologous MSCs	Chen 2004 [107]

Australia being a country with no incidence of BSE and vCJD, the use of certified FBS for hMSC ex vivo expansion is still accepted; no adverse events in terms of zoonoses transmission were observed; however, since the vCJD latency period may last many years, long-term follow-up is needed.